PET with [18F]VAT to see how nicotine affects brain acetylcholine in depression

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional, Phase 4 protocol uses PET imaging with the [18F]VAT tracer before and after administration of a transdermal nicotine patch to map cholinergic nerve-cell activity. The trial enrolls adults aged 18–65 with current major depressive disorder (MADRS ≥29) as well as non-depressed control participants. Imaging comparisons between pre- and post-nicotine scans aim to show how nicotine alters vesicular acetylcholine transporter–related signals in the brain. Safety monitoring and screening for recent nicotine use or medications that affect cholinergic function are included in the protocol.

Why it matters

Who can join: the full rules

Inclusion Criteria:

For Non-Depressed Participants:

* Age range 18 to 65 years old.
* Capacity to consent (able to read, understand, and sign informed consent).

For Participants with MDD

* Age range 18 to 65 years old.
* Capacity to consent (able to read, understand, and sign informed consent).
* Major Depressive Disorder (MDD) as primary diagnosis and currently in a major depressive episode
* Score of at least 29 on the Montgomery-Asberg Depression Rating Scale (MADRS).

Exclusion Criteria:

For Non-Depressed Participants:

* Nicotine use, including tobacco, e-cigarettes, nicotine patch, nicotine gum, within the past year \[except for occasional users, who cannot use nicotine products in the week before the scan\].
* Need for use of medication during the study that will affect cholinergic levels.
* Problematic drug/alcohol use that is judged sufficient to interfere with study procedures during the treatment period or impact participant safety.
* Significant active physical illness or neurological deficit that may affect brain function or imaging.
* Significant eye conditions such as keratoconus and/or need for rigid contact lenses.
* Current or lifetime history of a major psychiatric diagnosis.
* Any MRI contraindications, including recent tattoos, metal implants, pacemaker, metal prostheses, orthodontic appliances, or presence of shrapnel that are contraindicated for MRI.
* Any PET contraindications, including if study imaging will result in the participant receiving greater exposure than the research limit, or if participant is pregnant, currently breastfeeding, or planning to conceive during the course of study participation.
* Blood donation within 8 weeks of the \[18F\]VAT scan.

For Participants with MDD

* Nicotine use, including tobacco, e-cigarettes, nicotine patch, nicotine gum, within the past year \[except for occasional users, who cannot use nicotine products in the week before the scan\].
* Currently on effective antidepressant medications or need for use of medications that target the cholinergic system.
* Problematic drug/alcohol use that is judged sufficient to interfere with study procedures during the treatment period or impact participant safety.
* Significant active physical illness or neurological deficit that may affect the brain function or imaging.
* Significant eye conditions such as keratoconus and/or need for rigid contact lenses.
* Current or lifetime major psychiatric diagnosis other than MDD.
* Life-time history of psychosis or current psychosis.
* Significant risk for suicide.
* Any MRI contraindications, including recent tattoos, metal implants, pacemaker, metal prostheses, orthodontic appliances, or presence of shrapnel that are contraindicated for MRI.
* Any PET contraindications, including if study imaging will result in the participant receiving greater exposure than the research limit, or if participant is pregnant, currently breastfeeding, or planning to conceive during the course of study participation.
* Blood donation within 8 weeks of the \[18F\]VAT scan.

Where it's running

• Stony Brook University: Dept of Psychiatry
  Stony Brook, New York, United States Recruiting

Study contacts

• Principal investigator: Ramin Parsey, MD, PhD — Stony Brook University
• Study coordinator: Julianna Lizzul
• Email: julianna.lizzul@stonybrookmedicine.edu
• Phone: 631-638-0291

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Emotional Reactivity in Severe Alcohol Use Disorder and Depression Using Eye-Tracking and Physiological Measures

  This study tests how people with severe alcohol use disorder, major depressive disorder, both conditions, or neither, recognize and react to emotions using eye-tracking and physiological data.

  Recruiting Université Catholique de Louvain · Brussels, Belgium · NCT07925281

• Temporally Interfering Electrical Stimulation for Major Depressive Disorder

  This study tests whether noninvasive temporally interfering electrical stimulation can help people with major depressive disorder.

  Recruiting at 2 sites Tianjin Medical University General Hospital · Fuzhou, Fujian and 1 other locations · NCT07924917

• Affective Cognitive Training for mood disorders and their close relatives

  A six-week program combining virtual reality and computer exercises tests whether affective cognitive training helps people with mood disorders and their unaffected first-degree relatives.

  Recruiting Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital · Frederiksberg, Capital Region of Denmark · NCT07920302

• ALKS 7290 added to antidepressants for adults with major depression

  This study tests whether ALKS 7290, taken with current antidepressants, helps adults with major depressive disorder.

  Recruiting Phase 2 Alkermes, Inc. · Jacksonville, Florida · NCT07901179

• French Minds: a French, Multimodal Cohort Study of Severe Psychiatric Disorders and Healthy Controls

  This study tests whether people with mood, psychotic, or autism disorders can be grouped into more similar subtypes based on social withdrawal and anhedonia, across ages 15 to 60.

  Recruiting at 10 sites Fondation FondaMental · Besançon and 16 other locations · NCT07881016

• EEG-Guided TMS for Adults With Depression

  This study tests whether delivering intermittent theta burst stimulation (iTBS) timed to brain waves using EEG can improve treatment for adults with major depressive disorder who have not responded to usual antidepressants.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT07862205

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.